Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Share Class Description:
IKT: Ordinary SharesDescription
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 55.22 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | -19.3 | |||||
| 3-Year FCF Growth Rate | -60.2 | |||||
| 3-Year Book Growth Rate | -32.8 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.46 | |||||
| 9-Day RSI | 34.24 | |||||
| 14-Day RSI | 34.79 | |||||
| 6-1 Month Momentum % | 115 | |||||
| 12-1 Month Momentum % | -41.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.13 | |||||
| Quick Ratio | 4.13 | |||||
| Cash Ratio | 3.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -54.6 | |||||
| Shareholder Yield % | -99.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -103.63 | |||||
| ROA % | -88.23 | |||||
| ROIC % | -1889.58 | |||||
| ROC (Joel Greenblatt) % | -4806.22 | |||||
| ROCE % | -108.52 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | 0.23 | |||||
| EV-to-Forward-EBIT | -0.03 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-Forward-Revenue | 1358.04 | |||||
| EV-to-FCF | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 0.76 | |||||
| Price-to-Net-Cash | 0.83 | |||||
| Earnings Yield (Greenblatt) % | 434.78 | |||||
| FCF Yield % | -213.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibikase Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.57 | ||
| Beta | 1.4 | ||
| Volatility % | 169.31 | ||
| 14-Day RSI | 34.79 | ||
| 14-Day ATR ($) | 0.176887 | ||
| 20-Day SMA ($) | 1.63905 | ||
| 12-1 Month Momentum % | -41.23 | ||
| 52-Week Range ($) | 0.79 - 4.351199 | ||
| Shares Outstanding (Mil) | 6.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibikase Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibikase Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inhibikase Therapeutics Inc Frequently Asked Questions
What is Inhibikase Therapeutics Inc(IKT)'s stock price today?
The current price of IKT is $1.31. The 52 week high of IKT is $4.35 and 52 week low is $0.79.
When is next earnings date of Inhibikase Therapeutics Inc(IKT)?
The next earnings date of Inhibikase Therapeutics Inc(IKT) is 2024-05-15 Est..
Does Inhibikase Therapeutics Inc(IKT) pay dividends? If so, how much?
Inhibikase Therapeutics Inc(IKT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers